ReviewJournal of pathology and translational medicine2021
Molecular biomarker testing for non-small cell lung cancer: consensus statement of the Korean Cardiopulmonary Pathology Study Group.
Review in Journal of pathology and translational medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Characterization of pleural metastasis in non-small cell carcinomas undergoing intraoperative frozen section examination.Journal of thoracic disease · 2025Article
- Tumor immune microenvironment analysis of non-small cell lung cancer development through multiplex immunofluorescence.Translational lung cancer research · 2024Article
- The Advantage of Targeted Next-Generation Sequencing over qPCR in Testing for DruggableInternational journal of molecular sciences · 2024Article
- Clinical utility of the Oncomine Dx Target Test multi-CDx system and the possibility of utilizing those original sequence data.Cancer medicine · 2024Article
- A Novel Dual-labeled Peptide for Multimodal Imaging of EGFR with L858R Mutation.Current radiopharmaceuticals · 2024Article
- Problems in the Pathologic Diagnosis of Suspected Lung Cancer.Tuberculosis and respiratory diseases · 2023Article
- FACILITATE: A real-world, multicenter, prospective study investigating the utility of a rapid, fully automated real-time PCR assay versus local reference methods for detecting epidermal growth factor receptor variants in NSCLC.Pathology oncology research : POR · 2023Article
- Biomarker testing of cytology specimens in personalized medicine for lung cancer patients.Journal of pathology and translational medicine · 2022Review
- Usefulness of BRAF VE1 immunohistochemistry in non-small cell lung cancers: a multi-institutional study by 15 pathologists in Korea.Journal of pathology and translational medicine · 2022Article
- Landscape of EGFR mutations in lung adenocarcinoma: a single institute experience with comparison of PANAMutyper testing and targeted next-generation sequencing.Journal of pathology and translational medicine · 2022Article
- Alveolar Soft Part Sarcoma of the Uterus: Clinicopathological and Molecular Characteristics.Diagnostics (Basel, Switzerland) · 2022Article
- Mesonephric-like Adenocarcinoma of the Ovary: Clinicopathological and Molecular Characteristics.Diagnostics (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Molecular biomarker testing is the standard of care for non-small cell lung cancer (NSCLC) patients. In 2017, the Korean Cardiopulmonary Pathology Study Group and the Korean Molecular Pathology Study Group co-published a molecular testing guideline which contained almost all known genetic changes that aid in treatment decisions or predict prognosis in patients with NSCLC. Since then there have been significant changes in targeted therapies as well as molecular testing including newly approved targeted drugs and liquid biopsy. In order to reflect these changes, the Korean Cardiopulmonary Pathology Study Group developed a consensus statement on molecular biomarker testing. This consensus statement was crafted to provide guidance on what genes should be tested, as well as methodology, samples, patient selection, reporting and quality control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.